Opinion|Videos|December 8, 2025
Concluding Thoughts: Practical Tips, Resources, and More
Author(s)Jonathan M. Meyer, MD, DLFAPA
Summarizing key messages and reinforce the value of TDM in improving patient outcomes.
Advertisement
This video covers the following questions:
- If you could leave psychiatrists with 3 key takeaways about clozapine TDM, what would they be?
- How do you envision the role of TDM evolving as we move toward more personalized and precision-based psychiatry?
- Any final advice for clinicians looking to optimize clozapine treatment through better use of monitoring tools and data?
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
3
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5